ALPHAMAB-B(09966) releases annual performance, with a net loss of 114 million RMB in the year, turning from profit to loss year-on-year.

ALPHAMAB-B (09966) released its annual performance for the year ending December 31, 2025. The company achieved revenue of 566 million yuan, a decrease of 11.54% year-on-year; it incurred a loss of 114 million yuan during the year, a turnaround from profit to loss; with a loss per share of 0.12 yuan. The announcement stated that research and development expenses increased from 404 million yuan for the year ending December 31, 2024 to 572 million yuan for the year ending December 31, 2025, mainly due to (i) an increase in the number of ongoing clinical trials; (ii) the expansion of the company's clinical research scale; and (iii) progress in clinical trials of the company's candidate drugs. The table below provides details of research and development expenses for the year as divided by nature.